Answers are grounded in this paper and cite their sources.
Berberine is an isoquinoline alkaloid with a broad spectrum of pharmacological activities, but it suffers from limited bioavailability and inferior physicochemical properties. In the current study, several novel berberine derivatives were rationally designed and synthesized by systematic structural modifications at the 8, 9, 12, and 13 positions of the berberine core. To impart enhanced lipophilicity and more favorable drug-like properties to the target novel berberine derivatives, we incorporated solubility-enhancing features via Grignard reactions, O-alkylation, Suzuki cross-coupling, and piperazine-based derivatization. All products were purified and structurally characterized by established methods. Antimicrobial screening against Gramnegative, Grampositive, and fungal strains showed that the substituent at C9 decisively modulates activity, and the synthetic approach reported here provides a practical route to diverse, more active berberine analogs, laying a foundation for future SAR studies and therapeutic development.
No takes yet. Share an insight, caveat, or question.
Sangal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: